Soluble CD163, CTLA4, CD80 and IL33R showed a more marked increase in patients with CRS/MAS and IEC-HS compared to CRS alone or negative controls, thus representing promising biomarkers to distinguish CRS/MAS and IEC-HS from CRS and non-inflammatory new-onset cytopenia. This evidence concerns the gene CD80 and congenital rubella syndrome.